Compare SBH & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBH | INBX |
|---|---|---|
| Founded | 1964 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2006 | 2024 |
| Metric | SBH | INBX |
|---|---|---|
| Price | $18.77 | $77.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $22.00 | ★ $266.67 |
| AVG Volume (30 Days) | ★ 1.4M | 261.4K |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.88 | N/A |
| EPS | ★ 2.02 | N/A |
| Revenue | ★ $3,734,567,000.00 | $1,300,000.00 |
| Revenue This Year | $1.35 | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $9.38 | ★ N/A |
| Revenue Growth | 0.90 | ★ 550.00 |
| 52 Week Low | $11.54 | $57.30 |
| 52 Week High | $21.06 | $155.29 |
| Indicator | SBH | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 40.51 |
| Support Level | $15.09 | $69.57 |
| Resistance Level | N/A | $86.61 |
| Average True Range (ATR) | 0.92 | 7.68 |
| MACD | -0.01 | 0.53 |
| Stochastic Oscillator | 40.97 | 34.68 |
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. The company operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, Netherlands, and other geographical regions. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. The products offered by the company include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.